<DOC>
	<DOCNO>NCT00321698</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy together chemotherapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase I/II trial study side effect best dose docetaxel give together radiation therapy see well work treat patient undergo surgery high-risk localized prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Docetaxel Treating Patients Who Are Undergoing Surgery Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) neoadjuvant radiotherapy docetaxel patient undergo prostatectomy high-risk localized prostate cancer . - Determine pathologic response rate patient treat phase II dose . Secondary - Determine prostate-specific antigen ( PSA ) short-term response rate patient treat regimen . - Determine long-term safety regimen prior radical prostatectomy patient . - Determine clinical response regimen urologic examination patient . - Determine surgical margin status time prostatectomy patient treat regimen . - Determine effect regimen , term Health-Related Quality Life Expanded Prostate Cancer Index Composite ( EPIC ) urinary symptom score American Urological Association 's measure , patient . - Determine clinical progression-free rate patient treat regimen . - Identify pretreatment predictor response patient examine tissue biomarkers preserve pretreatment biopsy specimen . - Determine biologic impact regimen patient examine prostatectomy specimen . - Collect frozen serum future analysis correlative biomarkers . - Compare RNA content ( gene expression profile ) pre- post-treatment tumor specimen order describe molecular impact regimen prostate cancer . OUTLINE : This phase I , dose-escalation study docetaxel follow phase II study . All patient undergo biopsy prostate gather research-only specimens prior begin treatment . - Phase I : Patients undergo radiotherapy daily , 5 day week , 5 week . Patients also receive docetaxel IV day 1 , 8 , 15 , 22 , 29 . Treatment continue absence disease progression unacceptable toxicity . Approximately 4-6 week completion chemoradiotherapy , patient undergo radical prostatectomy . Cohorts 3-6 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . - Phase II : Patients undergo radiotherapy phase I . Patients also receive docetaxel MTD determine phase I undergo prostatectomy phase I . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>INCLUSION CRITERIA ; DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Localized disease , meet 1 follow stag criterion : Clinical stage T2b ( palpable bilateral movement ) disease Surgically resectable T3 disease Meets follow highrisk* feature : PSA ≥ 15 ng/mL Gleason grade ≥ 4+3 ( 4+3 , 4+4 , 5+any , 3+4 ) NOTE : *High risk define &gt; 50 % chance failure local therapy Plans undergo prostatectomy primary therapy No evidence lymph node ≥ 2 cm diameter pelvic CT scan Scan require patient PSA ≥ 40 ng/mL No evidence bone metastases bone scan PATIENT CHARACTERISTICS : Life expectancy ≥ 10 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 White blood cell ( WBC ) &gt; 3,000/mm^3 Neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Direct bilirubin normal Alanine aminotransferase ( ALT ) &lt; 2.0 time upper limit normal ( ULN ) ( 1.5 time ULN alkaline phosphatase [ AP ] &gt; 2.5 time ULN ) Alkaline phosphatase ( AP ) &lt; 4.0 time ULN No serious medical condition would preclude study treatment No malignancy within past 5 year except nonmelanoma skin cancer No peripheral neuropathy ≥ grade 2 No hypersensitivity drug formulate polysorbate 80 No significant contraindication corticosteroids No history scleroderma No active inflammatory bowel disease ( IBD ) IBD medically treat Inclusion patient remote history IBD discretion radiotherapist EXCLUSION CRITERIA ; PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior therapy prostate cancer , include follow : Conventional hormonal therapy ( e.g. , orchiectomy , luteinizing hormonereleasing hormone therapy , antiandrogen therapy , estrogen therapy ) Externalbeam radiotherapy brachytherapy Cryotherapy Cytotoxic chemotherapy No prior pelvic radiotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>